ByTrending Posts
Dyno Therapeutics and Roche Expand Strategic Partnership for…
October 24, 2024 Dyno Therapeutics has expanded its collaboration with Roche to advance next-generation adeno-associated virus (AAV) vectors…
Six Ways Johnson & Johnson is Leveraging AI…
October 10, 2024 Johnson & Johnson is at the forefront of integrating Artificial Intelligence (AI) to drive healthcare…
BullFrog AI Publishes Data Highlighting Potential of BF-114…
Gaithersburg, Md – Oct 9 2024 BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW), a technology-enabled drug development company…
ProJenX and Unlearn AI Collaborate to Advance AI-Powered…
San Francisco – September 27, 2024 ProJenX, a clinical-stage biotech company, has partnered with Unlearn AI to enhance…
Novartis and Generate:Biomedicines Announce Strategic AI-Driven Protein Therapeutics…
Somerville, MA — Sept 24, 2024 Combining AI innovation with pharma expertise to accelerate drug development and tackle…
Eli Lilly and Genetic Leap Forge $409M Strategic…
New York – Sept 24 2024 Eli Lilly and Company (NYSE: LLY) has entered into a landmark $409…
Rakovina Therapeutics and Variational AI Partner to Advance…
Vancouver, BC – September 17, 2024 Rakovina Therapeutics Inc. (TSX-V: RKV), a Canadian biopharmaceutical company focused on developing…
Gilead Expands AI-Driven Drug Discovery Capabilities Through Strategic…
BURLINGAME, California – Sept 10, 2024 Gilead Sciences, Inc. (Nasdaq: GILD) and Genesis Therapeutics have entered into a…
Sanofi Taps Atomwise in $1B+ AI Drug Pact…
Key Highlights San Francisco — Atomwise, a pioneer in artificial intelligence for small molecule drug discovery, has entered…
Trending Posts
Latest Stories
Did Merck’s 2025 Strategies, Deals, and Pipeline Strength Position It for Breakthrough Growth in 2026?
Merck concluded 2025 with a strong performance across its pharmaceuticals, vaccines, and oncology segments, demonstrating…
Did AstraZeneca’s 2025 Deals Lay the Groundwork for Transformative Growth Across Oncology, Immunology, and Rare Diseases in 2026?
In 2025, AstraZeneca executed a series of strategic collaborations, partnerships, and selective acquisitions designed to…
Can AstraZeneca’s 2025 Execution Propel It to Leadership Across Oncology, CVRM, and Immunology in 2026?
AstraZeneca concluded 2025 as a company demonstrating resilient performance, focused execution, and continued innovation across…
How Did Sanofi’s 2025 Deals Shape Its Strategy and What Do They Mean for the Future?
In 2025, Sanofi pursued a series of strategic collaborations, acquisitions, and licensing agreements aimed at…
Gallery
